Ibutamoren Mesylate

N/A

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameIbutamoren Mesylate
Drug Alias Nameibutamoren伊布莫仑伊布莫仑甲磺酸ibutamorenum伊布莫仑甲磺酸盐 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGhrelin/growth hormone secretagogue receptor agonists
TargetsGhrelin/growth hormone secretagogue receptor
Therapy Area/IndicationsGrowth hormone deficiencyHealthy AgingHip Fractures +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineSweden +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesLumos Pharma Inc
Inactive CompaniesUniversity Of VirginiaMerck Sharp & Dohme LLC
Active IndicationsGrowth hormone deficiency
Inactive IndicationsHealthy AgingHip FracturesRenal Insufficiency, Chronic +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG